Temsirolimus and Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma: a multi-center Phase 2 Study

BACKGROUND: Temsirolimus is an mTOR inhibitor with single-agent antitumor activity in patients with mantle cell lymphoma (MCL). We therefore tested the efficacy and toxicity of temsirolimus in combination with rituximab in patients with relapsed or refractory MCL. METHODS: Patients received temsirol...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Ansell, Stephen M., Tang, Hui, Kurtin, Paul J., Koenig, Patricia A., Inwards, David J., Shah, Keith, Ziesmer, Steven C., Feldman, Andrew L., Rao, Radha, Gupta, Mamta, Erlichman, Charles, Witzig, Thomas E.
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3106222/
https://ncbi.nlm.nih.gov/pubmed/21440503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(11)70062-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires